Logo image of RCAT

RED CAT HOLDINGS INC (RCAT) Stock Fundamental Analysis

NASDAQ:RCAT - Nasdaq - US75644T1007 - Common Stock - Currency: USD

6.35  -0.43 (-6.34%)

Premarket: 6.41 +0.06 (+0.94%)

Fundamental Rating

2

Overall RCAT gets a fundamental rating of 2 out of 10. We evaluated RCAT against 125 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of RCAT have multiple concerns. RCAT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RCAT has reported negative net income.
In the past year RCAT has reported a negative cash flow from operations.
In the past 5 years RCAT always reported negative net income.
RCAT had a negative operating cash flow in each of the past 5 years.
RCAT Yearly Net Income VS EBIT VS OCF VS FCFRCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

RCAT has a worse Return On Assets (-111.46%) than 91.20% of its industry peers.
The Return On Equity of RCAT (-210.70%) is worse than 88.80% of its industry peers.
Industry RankSector Rank
ROA -111.46%
ROE -210.7%
ROIC N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
RCAT Yearly ROA, ROE, ROICRCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCAT Yearly Profit, Operating, Gross MarginsRCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

More info and screens

3

2. Health

2.1 Basic Checks

RCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
RCAT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RCAT has been increased compared to 5 years ago.
RCAT has a better debt/assets ratio than last year.
RCAT Yearly Shares OutstandingRCAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RCAT Yearly Total Debt VS Total AssetsRCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 9.42 indicates that RCAT is not in any danger for bankruptcy at the moment.
RCAT has a Altman-Z score of 9.42. This is amongst the best in the industry. RCAT outperforms 90.40% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that RCAT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.44, RCAT is not doing good in the industry: 66.40% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 9.42
ROIC/WACCN/A
WACC9.34%
RCAT Yearly LT Debt VS Equity VS FCFRCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RCAT has a Current Ratio of 1.43. This is a normal value and indicates that RCAT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of RCAT (1.43) is worse than 77.60% of its industry peers.
A Quick Ratio of 0.57 indicates that RCAT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.57, RCAT is doing worse than 92.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.57
RCAT Yearly Current Assets VS Current LiabilitesRCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

RCAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.62%, which is quite good.
RCAT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -56.76%.
Measured over the past years, RCAT shows a very strong growth in Revenue. The Revenue has been growing by 176.68% on average per year.
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)-56.76%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-60.96%

3.2 Future

The Earnings Per Share is expected to grow by 39.49% on average over the next years. This is a very strong growth
RCAT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.37% yearly.
EPS Next Y23.5%
EPS Next 2Y51.01%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue Next Year341.83%
Revenue Next 2Y187.77%
Revenue Next 3Y123.37%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RCAT Yearly Revenue VS EstimatesRCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
RCAT Yearly EPS VS EstimatesRCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCAT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 56.60, the valuation of RCAT can be described as expensive.
RCAT's Price/Forward Earnings ratio is in line with the industry average.
RCAT is valuated expensively when we compare the Price/Forward Earnings ratio to 21.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 56.6
RCAT Price Earnings VS Forward Price EarningsRCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCAT Per share dataRCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
RCAT's earnings are expected to grow with 39.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.01%
EPS Next 3Y39.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCAT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RED CAT HOLDINGS INC

NASDAQ:RCAT (5/21/2025, 8:00:01 PM)

Premarket: 6.41 +0.06 (+0.94%)

6.35

-0.43 (-6.34%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners32.55%
Inst Owner Change-40.53%
Ins Owners18.14%
Ins Owner Change-7.25%
Market Cap574.74M
Analysts84.44
Price Target14.28 (124.88%)
Short Float %18.47%
Short Ratio3.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.72%
Min EPS beat(2)-58.73%
Max EPS beat(2)-2.71%
EPS beat(4)0
Avg EPS beat(4)-70.75%
Min EPS beat(4)-145.1%
Max EPS beat(4)-2.71%
EPS beat(8)1
Avg EPS beat(8)-71.65%
EPS beat(12)2
Avg EPS beat(12)-122.87%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-35.37%
Min Revenue beat(2)-37.31%
Max Revenue beat(2)-33.43%
Revenue beat(4)0
Avg Revenue beat(4)-19.69%
Min Revenue beat(4)-37.31%
Max Revenue beat(4)-1.15%
Revenue beat(8)2
Avg Revenue beat(8)-13.68%
Revenue beat(12)3
Avg Revenue beat(12)-23.64%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)40%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-27.66%
EPS NY rev (3m)-27.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)114.55%
Revenue NY rev (3m)114.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 56.6
P/S 90.02
P/FCF N/A
P/OCF N/A
P/B 21.26
P/tB 920.76
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)0.11
Fwd EY1.77%
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.07
BVpS0.3
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -111.46%
ROE -210.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.5%
Cap/Sales 2.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 0.57
Altman-Z 9.42
F-Score1
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)137.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y23.5%
EPS Next 2Y51.01%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-56.76%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-60.96%
Revenue Next Year341.83%
Revenue Next 2Y187.77%
Revenue Next 3Y123.37%
Revenue Next 5YN/A
EBIT growth 1Y-39.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.87%
EBIT Next 3Y56.58%
EBIT Next 5YN/A
FCF growth 1Y-63.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.9%
OCF growth 3YN/A
OCF growth 5YN/A